BioCorRx (BICX) AI Stock Analysis

• Market Cap: $9.47M
• Dividend Yield: N/A
• Average Volume (3M): 824.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: 3464.86%
• EPS Growth: 38.01%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.07
• Shares Outstanding: 23,685,343
• 10 Day Avg. Volume: 1,315
• 30 Day Avg. Volume: 824
• PEG Ratio: -0.09
• Price to Book (P/B): -0.33
• Price to Sales (P/S): 518.78
• P/FCF Ratio: -3.63
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: 15.00
• Enterprise Value/Gross Profit: 27.82
• Enterprise Value/Ebitda: -5.20
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.21
• Revenue Forecast (FY): $971.85K

• Rating: 41 Neutral
• Price Target: $0.38 ▲(19.38% Upside)
• Action: Reiterated Date: 01/15/26
• Date: Action: Reiterated 01/15/26

The score is primarily constrained by very weak financial performance—large ongoing losses, continued cash burn, and a balance sheet burdened by significant negative equity—despite a strong recent revenue rebound. Technicals also remain soft with the stock below major moving averages and negative MACD, while valuation support is limited due to negative earnings and no dividend.

Positive Factors

Revenue Rebound

A large TTM revenue rebound (+222.8% to ~$1.01M) signals renewed demand for BioCorRx’s recovery offerings. Sustained top-line growth provides the foundation to scale clinical programs, absorb fixed costs, and improve unit economics over the next several quarters if the trend continues.

Moderate Gross Margin

A ~33.7% gross margin indicates the business retains a material share of revenue to cover operating expenses. That margin level gives room for operating leverage as revenues grow, supporting a plausible pathway to improved operating profitability without requiring immediate, drastic cost restructuring.

Improving Cash Flow Trend

Free cash flow improving ~19.5% TTM shows management beginning to reduce cash burn and improve operational efficiency. While still negative, a consistent improvement trend reduces near-term financing pressure and, combined with revenue growth, supports a sustainable path toward positive cash generation.

Negative Factors

Negative Stockholders' Equity

Material negative equity (~-$12.8M) is a structural capital-structure weakness that limits financial flexibility and increases refinancing risk. It can impair the company’s ability to raise capital on favorable terms, negotiate with creditors, and execute growth plans without dilutive or costly financing.

Persistent Cash Burn

Sustained negative operating cash flow (~-$1.70M TTM) forces ongoing reliance on external financing or asset sales, constraining reinvestment in programs and scaling. Until operating cash flow turns positive, the business remains vulnerable to funding interruptions and higher capital costs.

Severely Negative Profitability

Extremely negative net margin (~-400%) and negative EBIT/EBITDA reflect a cost structure far above current revenue levels. Without structural margin improvement or sustained, sizable revenue expansion, profitability is unlikely, limiting free cash flow generation and long-term viability absent continued external support.

BioCorRx Business Overview & Revenue Model

Company Description

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

How the Company Makes Money

BioCorRx Inc. generates revenue through the sale of its addiction treatment products, particularly its naltrexone implant, which is distributed to healthcare providers and clinics specializing in addiction treatment. The company also makes money by offering a comprehensive recovery program that includes counseling and support services, which can be sold directly to treatment centers or licensed as a package. Additionally, BioCorRx may engage in partnerships with medical facilities and practitioners to expand the reach of its programs and products, contributing to its revenue streams.

BioCorRx Financial Statement Overview

Summary

Despite a sharp TTM revenue rebound (~$1.01M, +222.8%) and moderate gross margin (~33.7%), profitability and cash generation remain severely weak (net margin about -400%, materially negative EBIT/EBITDA, and ~-$1.70M TTM operating cash flow). The balance sheet is also highly stressed with significant negative stockholders’ equity (~-$12.8M), increasing financing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply to ~$1.01M (reported +222.8% growth), and gross margin is moderate at ~33.7%. However, profitability remains severely challenged: net margin is deeply negative (about -400%), with EBIT and EBITDA also materially negative, indicating the cost structure is still far above the current revenue base. Multi-year results show recurring net losses and highly volatile revenue levels, underscoring an early-stage/turnaround profile rather than an established earnings engine.

Balance Sheet

The balance sheet is highly stressed by persistent negative stockholders’ equity (TTM about -$12.8M), which is a major financial risk signal and limits flexibility. Total debt is ~$2.78M TTM, and while the reported debt-to-equity is negative (driven by negative equity), leverage risk remains elevated given ongoing losses. Total assets increased meaningfully in TTM (~$7.53M), but the capital structure (negative equity) remains the key weakness.

Cash Flow

Cash generation is weak with TTM operating cash flow of about -$1.70M and similarly negative free cash flow, implying continued cash burn to fund operations. Free cash flow improved versus the prior period (TTM growth ~19.5%), but it remains negative and therefore still dependent on external financing or balance sheet support. Cash flow performance has been consistently negative across the annual periods provided, indicating limited self-funding capability today.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2020
Income Statement
Total Revenue	1.01M	7.67K	89.16K	213.84K	48.27K	122.62K
Gross Profit	544.90K	6.00K	53.17K	198.56K	42.39K	26.67K
EBITDA	-2.91M	-3.59M	-2.68M	-3.15M	-4.48M	-2.83M
Net Income	-5.16M	-5.11M	-3.77M	-4.37M	-5.80M	-4.01M
Balance Sheet
Total Assets	7.53M	385.94K	388.89K	766.59K	819.98K	1.83M
Cash, Cash Equivalents and Short-Term Investments	287.69K	88.03K	65.22K	68.61K	85.84K	592.05K
Total Debt	7.88M	2.81M	1.81M	1.68M	1.77M	955.59K
Total Liabilities	20.30M	12.74M	10.34M	8.97M	7.78M	6.04M
Stockholders Equity	-13.48M	-12.12M	-9.82M	-8.08M	-6.84M	-4.09M
Cash Flow
Free Cash Flow	-1.70M	-1.10M	-1.85M	-2.04M	-3.59M	-2.16M
Operating Cash Flow	-1.70M	-1.10M	-1.85M	-2.04M	-3.54M	-2.15M
Investing Cash Flow	0.00	0.00	0.00	0.00	-50.00K	-9.23K
Financing Cash Flow	1.99M	1.12M	1.85M	2.02M	3.08M	107.30K

BioCorRx Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.32
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Neutral. The current price of 0.32 is above the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.32, and below the 200-day MA of 0.37, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 65.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BICX.

BioCorRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPS	58 Neutral	$662.41M	-2.57	-205.18%	―	―	-21.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$13.86M	-6.20	-8.75%	―	17.84%	-156.13%
CCEL	49 Neutral	$27.39M	-57.43	―	11.14%	-0.29%	94.56%
TOI	46 Neutral	$284.32M	-4.49	-3407.86%	―	21.67%	16.74%
CCM	44 Neutral	$15.80M	-0.70	―	―	-22.38%	56.66%
BICX	41 Neutral	$9.47M	-1.24	―	―	3464.86%	38.01%